ClinicalTrials.gg

Program

glovadalen

Also written as “UCB0022”.

Its studies are mostly in Parkinson Disease, led by UCB.

Furthest: phase 2, since Sep 20, 20234 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
UCB40 open or runningphase 2since Sep 20, 2023Apr 27, 2021none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 27, 2021First study: phase 1 study in Parkinson DiseaseFirst studyNCT04867642 · 100 enrolled · United Kingdom
  2. Sep 20, 2023Phase 2 study in Parkinson DiseaseNCT06055985 · 207 enrolled · United States
  3. May 12, 2025Phase 1 study in Healthy Study ParticipantsNCT06970301 · 32 enrolled · United States
  4. Oct 22, 2025Phase 1 study in Healthy VolunteersNCT07220551 · 14 enrolled · United States

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07220551Healthy Volunteers · United States1CompletedDec 16, 202514
NCT06970301Healthy Study Participants · United States1CompletedMay 29, 202632
NCT06055985Parkinson Disease · United States2CompletedMar 31, 2025207
NCT04867642Parkinson Disease · United Kingdom1CompletedFeb 27, 2023100

How it is read

Names in the registry

  • “UCB0022”, 3 entries
  • “glovadalen”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.